Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague
Fuente:
FierceBiotech
Antibody platform business OmniAb continues to rack up Big Pharma partnerships, with Eli Lilly signing off on up to $370 million biobucks tied to an ion channel program.